These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37269300)

  • 1. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
    McLaughlin V; Alsumali A; Liu R; Klok R; Martinez EC; Nourhussein I; Bernotas D; Chevure J; Pausch C; De Oliveira Pena J; Lautsch D; Hoeper MM
    Adv Ther; 2024 Jan; 41(1):130-151. PubMed ID: 37851297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
    Joshi SR; Liu J; Bloom T; Karaca Atabay E; Kuo TH; Lee M; Belcheva E; Spaits M; Grenha R; Maguire MC; Frost JL; Wang K; Briscoe SD; Alexander MJ; Herrin BR; Castonguay R; Pearsall RS; Andre P; Yu PB; Kumar R; Li G
    Sci Rep; 2022 May; 12(1):7803. PubMed ID: 35551212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.
    Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.
    Joshi SR; Atabay EK; Liu J; Ding Y; Briscoe SD; Alexander MJ; Andre P; Kumar R; Li G
    Front Cardiovasc Med; 2023; 10():1064290. PubMed ID: 36910526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Pulmonary Arterial Hypertension With Sotatercept: A Meta-Analysis.
    Uddin N; Ashraf MT; Sam SJ; Sohail A; Ismail SM; Paladini A; Syed AA; Mohamad T; Varrassi G; Kumar S; Khatri M
    Cureus; 2024 Jan; 16(1):e51867. PubMed ID: 38327917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From bench to bedside: The promise of sotatercept in hematologic disorders.
    Lan Z; Lv Z; Zuo W; Xiao Y
    Biomed Pharmacother; 2023 Sep; 165():115239. PubMed ID: 37516019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes.
    Nasrollahizadeh A; Soleimani H; Nasrollahizadeh A; Hashemi SM; Hosseini K
    Clin Cardiol; 2024 Jan; 47(1):e24173. PubMed ID: 37819149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging biologics for the treatment of pulmonary arterial hypertension.
    Hye T; Hossain MR; Saha D; Foyez T; Ahsan F
    J Drug Target; 2023 Jun; 31(5):1-15. PubMed ID: 37026714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension.
    Yung LM; Yang P; Joshi S; Augur ZM; Kim SSJ; Bocobo GA; Dinter T; Troncone L; Chen PS; McNeil ME; Southwood M; Poli de Frias S; Knopf J; Rosas IO; Sako D; Pearsall RS; Quisel JD; Li G; Kumar R; Yu PB
    Sci Transl Med; 2020 May; 12(543):. PubMed ID: 32404506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension.
    Ryanto GRT; Musthafa A; Hara T; Emoto N
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
    Sherman ML; Borgstein NG; Mook L; Wilson D; Yang Y; Chen N; Kumar R; Kim K; Laadem A
    J Clin Pharmacol; 2013 Nov; 53(11):1121-30. PubMed ID: 23939631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS.
    Walpurgis K; Thomas A; Vogel M; Reichel C; Geyer H; Schänzer W; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1152-1161. PubMed ID: 27649383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension.
    Auth R; Klinger JR
    Expert Opin Investig Drugs; 2023; 32(11):1025-1042. PubMed ID: 37881882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial.
    Kopeć G
    Cardiovasc Res; 2023 Dec; 119(16):e155-e157. PubMed ID: 37584249
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension.
    Condon DF; Agarwal S; Chakraborty A; Auer N; Vazquez R; Patel H; Zamanian RT; de Jesus Perez VA
    Chest; 2022 Apr; 161(4):1060-1072. PubMed ID: 34655569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.